Skip to search formSkip to main contentSkip to account menu

aflibercept

Known as: Vascular Endothelial Growth Factor Trap, VEGF Trap R1R2, VEGF Trap 
A protein comprised of segments of the extracellular domains of human vascular endothelial growth factor receptors 1 (VEGFR1) and 2 (VEGFR2) fused to… 
National Institutes of Health

Related topics

Related topics

10 relations
0.05 ML aflibercept 40 MG/ML Injection0.05 ML aflibercept 40 MG/ML Injection [Eylea]4 ML ziv-aflibercept 25 MG/ML Injection [Zaltrap]Vascular Endothelial Growth Factor A

Narrower (4)

AVE 0005EyleaZaltrapziv-aflibercept

Broader (2)

Recombinant Fusion ProteinsVascular Endothelial Growth Factor Receptor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Visual and Anatomic Outcomes after Conversion to Aflibercept in Neovascular Age-Related Macular Degeneration: 12-Month Results
Purpose To investigate 12-month outcomes of conversion to aflibercept in patients with neovascular age-related macular… 
2015
2015
Selecting revascularization strategies in patients with coronary disease.
The treatment of patients with coronary artery disease includes risk-factor modification (e.g., treatment of hypertension… 
2014
2014
Public biotech 2013—the numbers
2013 was truly a year to remember for the public biotech sector, with the largest wave of IPOs since the 2000–2001 bubble. 
2009
2009
Colon perforation during antiangiogenic therapy for malignant glioma.
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this… 
2009
2009
0D Modelling: a Promising Means for After-treatment Issues in Modern Automotive Applications
For modern automotive applications, after-treatment systems have become essential to respect the new emission standards. All the… 
2006
2006
Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors.
13061 Background: VEGF Trap is a potent angiogenesis inhibitor comprising portions of human VEGF receptor VEGFR1 (Flt-1) and… 
2006
2006
Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors.
13161 Background: VEGF Trap is a potent angiogenesis inhibitor comprising portions of human VEGF receptor VEGFR1 (Flt-1) and… 
2005
2005
A 1kW Phase-Shifted Full Bridge Converter incorporating Contact-less Transfer of Energy
This paper addresses the problem of reliable power transfer from the stationary to the rotating part of an airborne radar without… 
2004
2004
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies
3009 Background: Vascular Endothelial Growth Factor (VEGF) Trap is a potent angiogenesis inhibitor that binds VEGF-A 100- to 1000… 
2004
2004
Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.
3009 Background: Vascular Endothelial Growth Factor (VEGF) Trap is a potent angiogenesis inhibitor that binds VEGF-A 100- to 1000… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)